| scholarly article | Q13442814 |
| P50 | author | Maurice J Ahsman | Q56862900 |
| P2093 | author name string | Alfonso Iorio | |
| Erik Berntorp | |||
| Maria Elisa Mancuso | |||
| Andreas Tiede | |||
| Toshko Lissitchkov | |||
| Alexander Solms | |||
| Anita Shah | |||
| Sara Wiegmann | |||
| Tihomir Zhivkov | |||
| P2860 | cites work | Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B | Q24234413 |
| Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future | Q26853631 | ||
| Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A | Q28075081 | ||
| Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment | Q33535682 | ||
| The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study | Q33610284 | ||
| Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. | Q34522059 | ||
| Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia | Q34661163 | ||
| Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A | Q36000862 | ||
| Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. | Q37489013 | ||
| Defining severity of hemophilia: more than factor levels | Q38136573 | ||
| Considerations in individualizing prophylaxis in patients with haemophilia A. | Q38203021 | ||
| Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. | Q38739383 | ||
| Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit | Q38950839 | ||
| Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis | Q39957037 | ||
| Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. | Q41975229 | ||
| Treatment adherence in hemophilia | Q42371331 | ||
| Non-compartmental analysis | Q44470140 | ||
| Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. | Q45862229 | ||
| Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. | Q45863022 | ||
| A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). | Q45866554 | ||
| Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group | Q45873829 | ||
| Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. | Q45875309 | ||
| A survey of adherence to haemophilia therapy in six European countries: results and recommendations | Q45879477 | ||
| Guidelines for the management of hemophilia | Q45880345 | ||
| Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. | Q45882480 | ||
| Population pharmacokinetics of recombinant factor VIII Fc fusion protein | Q45885620 | ||
| Defining extended half-life rFVIII-A critical review of the evidence. | Q52597091 | ||
| BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies | Q59468800 | ||
| Measurement of anti-drug antibodies to biologic drugs | Q85898507 | ||
| Individualized PK-based prophylaxis in severe haemophilia | Q88066819 | ||
| Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A | Q88483168 | ||
| Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII | Q88586127 | ||
| Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: Results from an international laboratory study | Q89468400 | ||
| P433 | issue | 9 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| hemophilia A | Q2092064 | ||
| P304 | page(s) | 2035-2044 | |
| P577 | publication date | 2019-06-24 | |
| P1433 | published in | Annals of Hematology | Q15766509 |
| P1476 | title | Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A | |
| P478 | volume | 98 |
| Q99713537 | Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A | cites work | P2860 |
Search more.